Chimeric Antigen Receptor News and Research

RSS

CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus

New research at ACR Convergence 2023, the American College of Rheumatology's annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines.

7 Nov 2023

Overcoming T-cell exhaustion: A new hope for CAR-T cell therapy

CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments such as chemotherapy are unsuccessful.

6 Nov 2023

New bioreactor could accelerate access to cancer-killing immunotherapy

A new tool to rapidly grow cancer-killing white blood cells could advance the availability of immunotherapy, a promising therapy which harnesses the power of the body's immune response to target cancer cells.

26 Oct 2023

Researchers discover new way to trigger programmed cell death in cancer cells

A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.

24 Oct 2023

CAR T-cell therapy for multiple myeloma shows no difference in survival outcomes by race and ethnicity

Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.

19 Oct 2023

Engineered bacteria deliver synthetic targets to solid tumors

For several years, researchers have been successfully using chimeric antigen receptor (CAR) T cells to target specific antigens found on blood cells as a cure for patients with leukemia and lymphoma.

12 Oct 2023

New nanocapsule treatment boosts immune response against solid tumors

UCLA researchers have developed a new treatment method using a tiny nanocapsule to help boost the immune response, making it easier for the immune system to fight and kill solid tumors.

11 Oct 2023

New form of cellular immunotherapy shows promise against brain tumors in mice

Scientists from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) successfully tested a new form of cellular immunotherapy against brain tumors in mice for the first time.

26 Sep 2023

New CAR T cell therapy approach minimizes severe side effects

In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves modifying patients' T-cells to target cancer cells, resulting in remarkable success rates for previously intractable forms of cancer.

19 Sep 2023

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children.

22 Aug 2023

Unveiling hidden threats: clustering loops in CAR-T cells impact cancer therapy

How complementarity-determining region (CDR) loops in the single-chain variable fragment (scFv) influence chimeric antigen receptor (CAR)-T cell behavior.

14 Aug 2023

Ovarian cancer patients enrolled in first-in-human trial of CAR T cell therapy

Recently published preclinical data by City of Hope scientists shows the immunotherapy is effective. Advanced ovarian cancer patients are now being enrolled in a Phase 1 first-in-human trial.

10 Aug 2023

Study explores the diverse expression patterns of T cell priming markers across cancers

A recent study explored transcriptomics of T-cell priming markers (TPMs) across different cancers.

10 Aug 2023

Immunotherapy after stem cell transplantation effectively combats certain childhood nerve tumors

Scientists at St. Anna Children's Cancer Research Institute and the Eberhard Karls University of Tübingen have shown that immunotherapy after stem cell transplantation effectively combats certain nerve tumors in children.

9 Aug 2023

The immune-modulatory effect of lenvatinib investigated in new study

Researchers explore the effect of lenvatinib treatment on patients with advanced thyroid cancer.

9 Aug 2023

Tails on engineered T cells could help fight cancer

In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of cancer cells.

27 Jul 2023

Two infusions of IL-15-expressing CAR NK Cells boost survival in lymphoma mouse models

A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.

26 Jul 2023

Using a vaccine to boost the response of engineered T cells

Engineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. However, it hasn't worked as well for solid tumors.

5 Jul 2023

New project aims to improve the efficacy and safety of CAR T therapies for solid tumors

Partners in the international consortium CAR T-REX announce the awarding of a highly competitive EIC Pathfinder Open grant, following the positive evaluation of their project entitled 'CAR T Cells Rewired to Prevent EXhaustion in the Tumour Microenvironment'.

23 Jun 2023

First successful Phase 2 trial uses cutting-edge RNA CAR-T therapy to treat autoimmunity

Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

22 Jun 2023